Highlights Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
33.4 ^USD	+11.48%		+9.11%	+72.34%

Apr. 29	Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	MT
Mar. 22	North American Morning Briefing : Stocks Struggle After New Records	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	CI
Neurogene Announces Business Update and 2024 Outlook	Jan. 05	CI
Neurogene Completes Merger With Neoleukin Therapeutics	Dec. 19	MT
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	Dec. 17	CI
Neoleukin Therapeutics Board Approves Reverse Stock Split, Increase in Authorized Common Stock Capital to 500 Million	Dec. 15	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	23-09-22	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Neoleukin Therapeutics to Merge With Neurogene in All-Stock Deal	23-07-18	MT
Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. in a reverse merger transaction.	23-07-17	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Neoleukin Therapeutics, Inc. Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating Nl-201 in Combination with Keytruda® (Pembrolizumab)	22-05-16	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-09	CI
Neoleukin Therapeutics, Inc. Provides NL-201 Update	22-05-09	CI
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neurogene Inc.

Equities

NGNE

US64135M1053

Highlights

Filters